# reload+after+2024-01-22 16:47:14.935960
address1§7 Golda Meir Street
address2§Weizmann Science Park
city§Ness Ziona
zip§7403650
country§Israel
phone§972 8 931 3433
fax§972 8 931 3434
website§https://www.sol-gel.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
fullTimeEmployees§55
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Alon  Seri-Levy', 'age': 62, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 861000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gilad  Mamlok', 'age': 55, 'title': 'Chief Financial Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 640000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Itzik  Yosef', 'age': 47, 'title': 'Chief Operating Officer', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 316000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Moshe  Arkin', 'age': 70, 'title': 'Executive Chairman of the Board', 'yearBorn': 1953, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. David  Avnir', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tamar  Fishman Jutkowitz', 'age': 47, 'title': 'VP & General Counsel', 'yearBorn': 1976, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Karine  Neimann', 'age': 52, 'title': 'VP of Projects & Planning and Chief Chemist', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.381
priceToSalesTrailing12Months§26.535114
currency§USD
dateShortInterest§1702598400
forwardEps§-0.69
exchange§NGM
quoteType§EQUITY
shortName§Sol-Gel Technologies Ltd.
longName§Sol-Gel Technologies Ltd.
firstTradeDateEpochUtc§1517495400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§70a294e5-cf02-3acc-8f41-1a0eafe7bd33
gmtOffSetMilliseconds§-18000000
targetHighPrice§9.0
targetLowPrice§7.0
targetMeanPrice§8.0
targetMedianPrice§8.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§2
quickRatio§9.611
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
